Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirzepatide Titration to Reduce Side Effects (TiTRE) in Individuals With Obesity
NCT07574723Recruiting
- Sponsor
- Dasman Diabetes Institute
- Start
- May 2026
- Primary completion
- May 2029
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised trial of tirzepatide in obesity (2 arms), sponsored by Dasman Diabetes Institute. Primary endpoint: Time to discontinuation of the treatment regimen at 76 weeks. Started May 2026; status: recruiting.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07574723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07574723.